Aranesp Pre-Dialysis Medicare Coverage Near 100%; Medicaid Rate At 90%
Executive Summary
Medicare reimbursement for Aranesp (darbepoetin) is nearly 100% in pre-dialysis patients, Amgen Exec VP Sales & Marketing George Morrow said
You may also be interested in...
Aranesp USP listing
Amgen's Aranesp is accepted by U.S. Pharmacopeia for off-label indication of chemotherapy-associated anemia. Amgen filed a darbepoetin sBLA for the indication Sept. 19. Amgen estimates that 70% of Aranesp's potential market is as a chemotherapy adjunct therapy (1"The Pink Sheet" Jan. 28, p. 29). Aranesp was approved for treatment of anemia in chronic renal failure patients Sept. 18...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011